# A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

> **NCT06709014** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Annovis Bio Inc.** · enrollment: 760 (estimated)

## Conditions studied

- Early Alzheimers Disease

## Interventions

- **DRUG:** buntanetap/posiphen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06709014
- **Lead sponsor:** Annovis Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-04
- **Primary completion:** 2027-12
- **Final completion:** 2028-06
- **Target enrollment:** 760 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06709014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06709014, "A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06709014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*